Science
Type 1 Diabetes
Explore
Type 1 diabetes mellitus (T1DM) is characterized by deficient insulin production, requiring daily or weekly administration of insulin to manage blood glucose levels. According to the Type 1 Diabetes Index, 8.7 million people are living with T1DM around the world.
There are limited treatment options for patients living with T1DM. The most widely used treatment option for such patients is administration of exogenous insulin with frequent monitoring of blood glucose levels. In addition, frequency, dose, and method varies on a case-by-case basis. As such, there exists significant unmet medical need to help such patients manage their glucose, simplify their day-to-day lives, and avoid associated complications with T1DM (e.g. cardiovascular disease).
YG1699 carries unique potential to help patients with T1DM better control their blood glucose levels, particularly after meals, and improve their overall quality of life. In addition, the associated benefits of dual SGLT1 and SGLT2 inhibition may reduce the risks associated with diabetes, including cardiovascular disease and diabetic nephropathy.
